Canada markets closed

Treatment.com AI Inc. (TREIF)

OTC Markets OTCQB - OTC Markets OTCQB Delayed Price. Currency in USD
Add to watchlist
0.2700-0.0146 (-5.13%)
At close: 10:53AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.2846
Open0.2700
Bid0.2677 x 0
Ask0.2800 x 0
Day's Range0.2700 - 0.2700
52 Week Range0.0210 - 1.1940
Volume5,000
Avg. Volume23,465
Market Cap10.596M
Beta (5Y Monthly)-0.28
PE Ratio (TTM)N/A
EPS (TTM)-0.1600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Treatment.com AI and Novus Health Partnership Expands Access to its Global Library of Medicine (GLM)

    VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with Health Care Services International Inc (o/a Novus Health). (“Novus Health”) to explore utilization of Treatment’s proprietary Global Library of Medicine (“GLM”) to further enhance Novus Health’s Health Risk Assessment programs. Treatment is partnering with Novus Health, an acknowledged leader

  • GlobeNewswire

    Treatment.com AI Announces Appointment of Richard Atkins as Chief Operating Officer and Executive Team member

    VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights is pleased to announce the appointment of Richard Atkins as Chief Operating Officer and a member of the executive team. Mr. Atkins brings to the business a successful career with over 30 years’ experience in international sales, partnerships, executive manage

  • GlobeNewswire

    Treatment.com AI Announces Contract Renewal with Leading US Medical School

    VANCOUVER, British Columbia, May 01, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is excited to announce one of the leading US medical schools has agreed to a contract renewal utilizing Treatment’s Medical Education Suite (“MES”). Treatment is also in discussions with a number of other medical and nursing schools, both in the US and internationally. As reported previously, the market in the US alone comprises 300 medical sc